Drugs / Ga68-FAPI-46
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07273188 | Jan 2026 → Feb 2027 expected | Crohn disease | Mayo Clinic | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06769828 | Feb 2025 → Apr 2026 overdue | colorectal cancer | Koo Foundation Sun Yat-Sen Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ga68-FAPI-46 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07273188 ↗ |
| Known as | 68Ga-FAPI-46 | “Gallium-68-labeled fibroblast activation protein inhibitor-46 (68Ga-FAPI-46) , 5 mCi ±10%, IV” NCT07273188 ↗ |
| Modality | Diagnostic / imaging agent | “Ga-68-FAPI-46, a novel imaging agent targeting fibroblast activation protein (FAP)” NCT06769828 ↗ |
| Route | Intravenous | “Ga-68-FAPI-46 will be administered via intravenous injection” NCT06769828 ↗ |
| Target | FAP | “targeting fibroblast activation protein (FAP)” NCT06769828 ↗ |